Defining and measuring negative symptoms of schizophrenia in clinical trials

@article{Marder2014DefiningAM,
  title={Defining and measuring negative symptoms of schizophrenia in clinical trials},
  author={Stephen R. Marder and Brian Kirkpatrick},
  journal={European Neuropsychopharmacology},
  year={2014},
  volume={24},
  pages={737-743}
}
Recent attention has focused on negative symptoms as a target for new therapeutic approaches including pharmacological agents, medical devices, and psychosocial treatments. Each of these approaches requires an instrument for measuring the severity of negative symptoms as well as changes in severity over time. The instrument selected should provide coverage for the domains of negative symptoms; it should be sensitive to change; it should be reliable and relatively brief; and it should be useful… Expand
Treating Negative Symptoms in Schizophrenia: an Update
TLDR
From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes. Expand
Negative symptoms of schizophrenia: new developments and unanswered research questions.
TLDR
If substantial progress is to be made in the understanding and treatment of negative symptoms, then advances in concepts and assessment should be integrated into the design of future studies of these symptoms. Expand
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
TLDR
The lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes, and further research to identify and characterize novel pharmacology treatments is greatly needed. Expand
Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.
  • K. Kaneko
  • Psychology, Medicine
  • Yonago acta medica
  • 2018
TLDR
Using functional neuroimaging techniques, the size of these therapy-induced beneficial changes in neurocognitive performance has been demonstrated to be correlated with the degree of the changes in brain activation during performing some cognitive tasks in the prefrontal and temporal cortices, which suggests neurobiological effects are exerted by psychosocial cognitive remediation treatments. Expand
Clinical management of negative symptoms of schizophrenia: An update.
TLDR
A critical review of the current pharmacological, non-pharmacological and psychosocial treatments available for NSS is presented here, using data retrieved from the MEDLINE/PUBMED, the Cochrane Database of Systematic Reviews and the ClinicalTrials.gov databases. Expand
EPA guidance on assessment of negative symptoms in schizophrenia
TLDR
This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. Expand
Measuring negative symptom change in schizophrenia: considering alternatives to self-report
TLDR
The purpose of this article is to highlight the limitations in current assessment measures for negative symptoms and discuss the advantages of quantitative objective measurement, particularly in the context of clinical trial research. Expand
Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases
TLDR
The evolution of concepts and assessment modalities relevant to PPNS, data on prevalence of DS and PNS, as well as studies on clinical, neuropsychological, brain imaging electrophysiological and psychosocial functioning aspects of DSand PNS are reviewed. Expand
Psychometric evaluation of the negative syndrome of schizophrenia
TLDR
Current instruments for assessing the negative syndrome of schizophrenia were classified into two categories according to their content validity and assessment approach as first- or second-generation instruments, with the NSA being considered a transitional instrument between the two. Expand
Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS)
TLDR
The Spanish version of the CAINS appears to be a valid tool for measuring negative symptoms in schizophrenia and correlated significantly with the SANS and PANSS negative symptom scale. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Next-generation negative symptom assessment for clinical trials: Validation of the Brief Negative Symptom Scale
TLDR
Results indicated that the BNSS has excellent internal consistency and temporal stability, as well as good convergent and discriminant validity in its relationships with other symptom rating scales, functional outcome, self-reported anhedonia, and neuropsychological test scores. Expand
The positive and negative syndrome scale (PANSS) for schizophrenia.
TLDR
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment. Expand
The NIMH-MATRICS consensus statement on negative symptoms.
TLDR
A consensus development conference was held to review the data relating to the existence of separate domains within negative symptoms, as a prerequisite for choosing appropriate measures of these domains in clinical trials and to examine issues that may interfere with treatment development. Expand
Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS)
TLDR
Results indicate that the CAINS is a promising new measure for quantifying negative symptoms in clinical neuroscience and treatment studies. Expand
Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia
TLDR
The relationship between negative symptom change and the change in functional outcomes is complex, and points to potential issues in selection of assessments. Expand
Negative symptoms in schizophrenia. Definition and reliability.
  • N. Andreasen
  • Psychology, Medicine
  • Archives of general psychiatry
  • 1982
TLDR
The developed Scale for the Assessment of Negative Symptoms has excellent interrater reliability and the five symptom complexes defined by the scale have good internal consistency, which indicates that the conceptual organization of the scale is also cohesive. Expand
The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations.
  • N. Andreasen
  • Psychology, Medicine
  • The British journal of psychiatry. Supplement
  • 1989
TLDR
The SANS is complemented by a Scale for the Assessment of Positive Symptoms (SAPS), which permits detailed evaluation and global ratings of hallucinations, delusions, positive formal thought disorder and bizarre behaviour and taken together, the two scales provide a comprehensive set of rating scales. Expand
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.
TLDR
It is suggested that distinct subgroups of patients with elevated AA or DE can be identified within the broader diagnosis of schizophrenia and that these subgroups show clinically meaningful differences in presentation. Expand
The structure of negative symptoms within schizophrenia: implications for assessment.
TLDR
Findings suggest that this construct is multidimensional with at least 2 factors (involving diminished expression and anhedonia-asociality) and the importance of employing assessments that provide adequate coverage of the broad domain of negative symptoms. Expand
The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training.
TLDR
Findings suggest that clinicians from a variety of geographic practices can, after brief training, use the 4-item Negative Symptom Assessment effectively to rapidly assess negative symptoms in patients with schizophrenia. Expand
...
1
2
3
4
...